Navigation Links
Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting
Date:5/20/2009

SAN DIEGO, May 20 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will be presented during a poster session entitled Multianalyte Biomarker Blood Test to Aid in Diagnosis, Treatment and Management of Major Depressive Disorder, at the American Psychiatric Association Annual Meeting, May 20, 2009.

The blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the paradigm used for neuropsychiatric diagnosis and patient management, primarily clinical interviews. Our approach differs from other investigators seeking to utilize single or groups of single biomarkers to characterize or identify patients with MDD by use of multiple markers and the construction of a unique diagnostic hyperspace mapping technology.

"We are pleased to present this clinically important blood test to the psychiatric community at the APA meeting," stated Stan Sewitch, President and CEO of Ridge. "We believe the assay results provide an objective adjunct to a patient's diagnosis and management, while at the same time providing the research community with a valuable tool for optimization of studies."

The poster will be presented by Dr. Perry Renshaw, Chief Medical Officer of Ridge Diagnostics and Director of Magnetic Resonance, Utah Brain Institute, Professor of Psychiatry, University of Utah School of Medicine.

Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough, first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company's products are derived from a proprietary Human Biomarker Library(TM) and Biomarker Hyper-mapping (BHyperMap(TM) )technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic platform. Ridge Diagnostics testing services are provided through its CLIA certified laboratory in North Carolina, and it is developing a kit version for future distribution. The company is located in San Diego, CA and Research Triangle Park, NC.


'/>"/>
SOURCE Ridge Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
2. Parkinsons Disease Foundation Awards $300,000 in Bridge Funding for Innovative Research Projects
3. Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
4. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
5. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
6. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
7. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
8. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
9. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
11. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):